Christine Surka,Liqing Jin,Nathan Mbong,Chin-Chun Lu,In Sock Jang,Emily Rychak,Derek Mendy,Thomas Clayton,Elizabeth Tindall,Christy Hsu,Celia Fontanillo,Eileen Tran,Adrian Contreras,Stanley W K Ng,Mary Matyskiela,Kai Wang,Philip Chamberlain,Brian Cathers,James Carmichael,Joshua Hansen,Jean C Y Wang,Mark D Minden,Jinhong Fan,Daniel W Pierce,Michael Pourdehnad,Mark Rolfe,Antonia Lopez-Girona,John E Dick,Gang Lu

Abstract:A number of clinically validated drugs have been developed by repurposing the CUL4-DDB1-CRBN-RBX1 (CRL4CRBN) E3 ubiquitin ligase complex with molecular glue degraders to eliminate disease-driving proteins. Here, we present the identification of a first-in-class GSPT1-selective cereblon E3 ligase modulator, CC-90009. Biochemical, structural, and molecular characterization demonstrates that CC-90009 coopts the CRL4CRBN to selectively target GSPT1 for ubiquitination and proteasomal degradation. Depletion of GSPT1 by CC-90009 rapidly induces acute myeloid leukemia (AML) apoptosis, reducing leukemia engraftment and leukemia stem cells (LSCs) in large-scale primary patient xenografting of 35 independent AML samples, including those with adverse risk features. Using a genome-wide CRISPR-Cas9 screen for effectors of CC-90009 response, we uncovered the ILF2 and ILF3 heterodimeric complex as a novel regulator of cereblon expression. Knockout of ILF2/ILF3 decreases the production of full-length cereblon protein via modulating CRBN messenger RNA alternative splicing, leading to diminished response to CC-90009. The screen also revealed that the mTOR signaling and the integrated stress response specifically regulate the response to CC-90009 in contrast to other cereblon modulators. Hyperactivation of the mTOR pathway by inactivation of TSC1 and TSC2 protected against the growth inhibitory effect of CC-90009 by reducing CC-90009-induced binding of GSPT1 to cereblon and subsequent GSPT1 degradation. On the other hand, GSPT1 degradation promoted the activation of the GCN1/GCN2/ATF4 pathway and subsequent apoptosis in AML cells. Collectively, CC-90009 activity is mediated by multiple layers of signaling networks and pathways within AML blasts and LSCs, whose elucidation gives insight into further assessment of CC-90009s clinical utility. These trials were registered at www.clinicaltrials.gov as #NCT02848001 and #NCT04336982).

Identification and Characterization of Novel Small-Molecule Enhancers of the CUL3 LZTR1 E3 Ligase KRAS Complex

Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex

CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets Acute Myeloid Leukemia Blasts and Leukemia Stem Cells.

Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Targeting Cul3-scaffold E3 ligase complex <i>via</i> KLHL substrate adaptors for cancer therapy

Targeting cancer with small-molecule pan-KRAS degraders

Defeat Mutant KRAS with Synthetic Lethality.

A Novel Strategy for Identifying Non-covalent KRas Inhibitors

One Step Closer to Targeting RAS.

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

KRAS is Vulnerable to Reversible Switch-Ii Pocket Engagement in Cells

Novel druggable space in human KRAS G13D discovered using structural bioinformatics and a P-loop targeting monoclonal antibody

Targeting cancer with small molecule pan-KRAS degraders

A Suite of Biochemical and Cell-Based Assays for the Characterization of KRAS Inhibitors and Degraders

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D

Reversible Small Molecule pan-Ras Inhibitors Display Tunable Affinity for the Active and Inactive forms of Ras.

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C